Benoit Lattuca, Cedric Mazeau, Guillaume Cayla, Grégory Ducrocq, Paul Guedeney, Mikael Laredo, Raphaëlle Dumaine, Mohamad El Kasty, Petr Kala, Mohammed Nejjari, Ota Hlinomaz, Olivier Morel, Olivier Varenne, Florence Leclercq, Laurent Payot, Christian Spaulding, Farzin Beygui, Grégoire Rangé, Zuzana Motovska, Jean-Jacques Portal, Eric Vicaut, Jean-Philippe Collet, Gilles Montalescot, Johanne Silvain
BACKGROUND: Whether ticagrelor in chronic coronary syndrome patients undergoing complex percutaneous coronary intervention (PCI) can prevent cardiovascular events is unknown. OBJECTIVES: The authors sought to evaluate outcomes of complex PCI and the efficacy of ticagrelor vs clopidogrel in stable patients randomized in the ALPHEUS (Assessment of Loading with the P2Y12 inhibitor ticagrelor or clopidogrel to Halt ischemic Events in patients Undergoing elective coronary Stenting) trial...
February 12, 2024: JACC. Cardiovascular Interventions